News Hub | News Direct

Record 40,000 Transplants Honors Legacy of Donors

United Network for Organ Sharing

Today, Dec. 17, 2021, the United States has officially surpassed 40,000 transplants in one year, a historic first for the nation. This is according to United Network for Organ Sharing (UNOS), the engine that powers the national organ donation and transplantation system under contract with the federal government. 2020 marked the 10th consecutive record-breaking year for organ donations from deceased donors and the 8th in a row for deceased donor transplants. “Reaching 40,000 organs transplants in a single year is a testament to the lifesaving work being done day in and day out that makes our donation and transplantation system the highest performing in the world,” said Matthew Cooper, M.D., president of the UNOS Board of Directors. "It is also a testament to the generosity of so many inspiring donors and their courageous families who gave the gift of life. “This news serves as a reminder that no matter what challenges we face as a nation, our community of doctors, patients, donor families, hospitals, organ procurement professionals, and advocates are dedicated to building on past successes to save even more lives. But there is always more work to do.” As of today, 106,962 men, women and children are on the waiting list for a transplant, which is at the lowest it has been since 2009. The list topped 124,000 at its height in 2014. "Every one of us has the potential to save multiple lives by registering to be an organ, tissue and eye donor," Cooper said. Learn more about organ donation and transplantation and how to register to be a donor at www.unos.org. Matthew Cooper, M.D., FACS, is president of the UNOS Board of Directors, Director of Kidney and Pancreas Transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital, and a professor in the department of surgery at Georgetown University School of Medicine. ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Eric Steigleder +1 804-782-4730 eric.steigleder@unos.org Company Website https://unos.org

December 17, 2021 06:43 PM Eastern Standard Time

Image

METER Group Unveils Major Update to AQUALAB Vapor Sorption Analyzer Software

METER Group, Inc.

Moisture Analysis Toolkit enables food and pharma manufacturers to address ingredient source changes, accelerate product formulation, extend shelf life, and employ the most cost-effective packaging using research-tested predictive models that present complex isotherm and water activity data as clear, actionable insights METER Group, Inc. USA (METER) today unveiled a major update to the AQUALAB Vapor Sorption Analyzer (VSA) Moisture Analysis Toolkit, enabling food and pharma companies to harness analytics and predictive modeling that accelerates product formulation, maximizes cost-efficiency of packaging, and extends shelf life. The AQUALAB VSA Moisture Analysis Toolkit (MAT) is a first-of-its-kind, intuitive, full-featured modeling solution that transforms moisture data into solutions using research-tested predictive models. This software helps overcome key water-related research and development challenges. It is particularly relevant as food manufacturers turn to high-tech solutions to increase profitability in the face of supply chain issues and consumer concern over safety and sustainability. Like most manufacturers, food producers are increasingly impacted by supply chain shortages. The pandemic has exacerbated existing ingredient sourcing problems caused by climate change. With the Moisture Analysis Toolkit, manufacturers can use high-resolution moisture data to predict the effect of new ingredient candidates on moisture in the final product. “In a new supplier situation, our clients rely on the toolkit to make faster decisions and react quickly to new ingredient sourcing,” says METER Executive Vice President Takuya Ohki. “That’s what the toolkit is all about—faster, data-driven decisions that allow our clients to stay competitive in a fast-changing marketplace.” Ohki says that data-driven decision making is at the heart of the MAT, which includes tools for selecting the correct packaging and determining shelf life. “Historically, companies have tended to over-package and set a conservative best-by date. Now consumers are pushing companies to address issues of 30-40 percent waste in the food supply—while still demanding a mold-free product. Tackling safety and sustainability in tandem requires our best use of science. Too much of this research is still not implemented in industry. The Moisture Analysis Toolkit is something designed to make this science immediately accessible, to allow food manufacturers to solve these problems today.” The MAT takes advantage of a unique moisture map created by METER Group’s AQUALAB VSA. The VSA generates a high-resolution isotherm called a Dynamic Dewpoint Isotherm (DDI) curve. DDI curves can save companies months spent identifying a critical water activity in low and intermediate moisture food and pharmaceutical products, because they clearly illustrate the change in sorption properties. While competitor instruments use just the DVS method, METER Group’s MAT not only delivers DVS isotherms, but it also provides truly dynamic high-resolution DDI isotherm curves, uncovering granular details which have never been seen before. Unlocking access to these critical insights allows for more precise formulation, more accurate predictions, and more complete product knowledge. The business benefits and value are significant. For example, a dry ingredients company struggling with excessive labor, time, and space spent on shelf-life studies reduced the amount of physical shelf-life tests by 75 percent, cutting expenditures on testing from $300,000 to less than $50,000 per year. METER’s Moisture Analysis Toolkit also lets manufacturers work backward, picking a final water activity that maximizes shelf life and then getting guidance on specific formulation decisions around ingredient selection. This not only makes the formulation process more precise, but also speeds it up. A cold press bar company used the MAT with VSA-generated DDI isotherms to assess moisture migration during the R&D process, allowing them to release new products 5x faster and bring new flavors to market before competitors. “We see our clients succeeding from a profitability standpoint, but to me, that’s only part of the equation,” says Ohki. “The Moisture Analysis Toolkit empowers food and pharma companies to eliminate waste and inefficiencies across their respective supply chains on an unprecedented scale. That’s about more than profitability—it’s about putting existing science to work on the big problems we have to tackle as a society.” About METER Group METER Group, a Decagon and UMS combined company, delivers real-time, high-resolution data that fuels production and processes for the food quality, environmental research, urban and agriculture sectors. Through the power of its employees, METER combines science, engineering, and design expertise to turn physical measurements into useful information. Learn more at www.metergroup.com. Contact Details JMRConnect Mostafa Razzak +1 202-904-2048 m.razzak@jmrconnect.net

December 16, 2021 08:30 AM Eastern Standard Time

Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California

G Medical Innovations Holdings

TEL AVIV and NEW YORK, Dec. [16], 2021 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the "Company") today announced the pricing of a private placement in the form of a convertible note in the principal amount of $5,000,000 that has a two-year maturity and a fixed conversion price. Proceeds to be used to launch 25 Covid-19 testing centers in California in Q1, 2022. The first six locations are currently in operation as of Wednesday, December 15, 2021. G Medical Innovations Holdings Ltd., a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, Known for its groundbreaking technology, remote patient monitoring devices and services utilized by hospitals and cardiologists across the country, GMedical’s innovative Prizma monitoring device will be offered direct-to consumer for the first time at these testing locations, as part of an aggressive company direct-to-consumer strategy. Prizma is a user-friendly cell phone-sized device that can help monitor user’s vital signs, providing to-the-minute readings for ECG, temperature, oxygen saturation, heart rate, stress levels and blood pressure, help track body weight and glucose levels. Data is presented directly to the user and the designated care provider. Prizma can also be prescribed by physicians to patients with cardiac or respiratory disease, diabetes and other health issues. With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales. “By offering Prizma at our Covid19 testing sites we are empowering consumers to measure and monitor their vital signs post testing, in the comfort of their own home,” said G Medical CEO Dr. Yacov Geva. “This unique opportunity to introduce our Prizma device to customers face-to-face at the point of sale is an important step forward in our company’s direct-to-consumer initiative EF Hutton, division of Benchmark Investments, LLC, acted as exclusive placement agent for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses the use of proceeds from the private placement, plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022, its direct-to-consumer strategy and the benefits and advantages of its Prizma medical device. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, G Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical is not responsible for the contents of third-party websites. Contact: G Medical Service +972 8-958-4777 service@gmedinnovations.com Contact Details G-Medical Innovations Holdings Ltd, Oren Cohen +972 8-958-4786 orenc@gmedinnovations.com Company Website https://gmedinnovations.com/

December 16, 2021 07:00 AM Eastern Standard Time

Completed Redwood Genome Sequence Reveals Genes for Climate Adaptation and Offers Insights into Genetic Basis for Survival

Save the Redwoods League

Save the Redwoods League, University of California, Davis, Johns Hopkins University, University of Connecticut and Northern Arizona University today announced new research that identifies the makeup of the coast redwood and giant sequoia genomes. The information helps scientists and conservationists better understand the genetic basis for these species’ ability to adapt to their changing environments. Through comparative analysis, the research also indicates that the coast redwood genome evolved from a single ancestral species. Today’s announcement follows the official publication of the coast redwood genome research this week in G3: Genes, Genomes, Genetics. The researchers previously made available the completed giant sequoia genome sequence, published in G3 in November 2020. The coast redwood and giant sequoia genome sequence data is available to the scientific community on Neale Lab’s UC Davis website. “It’s remarkable how far genomics research has come since we undertook this challenge in 2017,” said David Neale, Ph.D., plant sciences professor emeritus at UC Davis and lead author on the new coast redwood genome research. “Our work on the coast redwood and giant sequoia genomes will enable us to develop modern genetic tools that can be used in the restoration and conservation of these ecologically important tree species.” The League and its research partners launched the Redwood Genome Project in 2017. Project partners outlined an ambitious plan to fully sequence the coast redwood and giant sequoia genomes for the first time, using new conifer genetic sequencing techniques. The genomic resources and screening tools that can now be developed will allow researchers to quickly assess evolutionary adaptive potential in these forests and ultimately inform forest restoration and management plans. The Coast Redwood Genome The coast redwood is the world’s tallest tree, and its genome is among the most complex sequenced. Nearly nine times larger than the human genome, it is also the second-largest genome sequenced. The redwood genome has 26.5 billion base pairs of DNA, and it is hexaploid, meaning redwoods have six sets of chromosomes. Humans have 3 billion base pairs of DNA and are diploid, with two sets of chromosomes. When comparing the coast redwood genome sequence to that of other conifer species, researchers found hundreds of gene families that are unique to the coast redwood. Many of these are genes that help the trees respond to stress and play a role in resistance to fungal disease, detoxification, repair after injury and the synthesis of flavonoids, which help fight stress on the cellular level. The new research also sheds additional light on the origin of the rare and large hexaploid genome of the coast redwood. Multiple genes exist in triplicate, and those copies share more similarities to each other than to the sequences of other species. This analysis supports the hypothesis that the redwood genome originated from a single ancestral species (autopolyploidy), rather than through hybridization with other conifer species. The Giant Sequoia Genome The giant sequoia is the world’s largest tree species and among the oldest on the planet. As reported by the research team in November 2020, its genome contains 8.125 billion base pairs of DNA. Similar to the human genome, the giant sequoia genome is diploid. The reference genome produced for this study represents the first genome sequenced in the Cupressaceae family, and it lays a foundation for using genomic tools to aid in giant sequoia conservation and management. The genomes of conifers are three to 10 times larger than the human genome. They are highly repetitive and complex. The first conifer genomes ever sequenced were the Norway spruce in 2013 and loblolly pine in 2014, 10 years after the human genome was completed. Sequencing conifer genomes was not previously feasible due to economic and technological limitations. With technological advancements that also reduced the cost, 10 conifer genomes have now been sequenced, including the coast redwood and giant sequoia. The reference genome sequences of coast redwood and giant sequoia enabled the preliminary identification of genes that determine drought-related traits and those that determine adaptation to the environment. These discoveries are reported in papers published in The Plant Journal and Genes. About the Redwood Genome Project Save the Redwoods League has provided strategic guidance and funding for the Redwood Genome Project specifically to inform forest restoration and stewardship activities that will maintain the adaptive genetic diversity of the coast redwood and giant sequoia forests. In the last 160 years, commercial logging and clearcutting claimed 95% of the coast redwood range and about one-third of the giant sequoia range. In 2020, an estimated 10% to 14% of giant sequoia died from high-intensity wildfires, and in some areas, the seedbank also died. Two wildfires also burned through large sections of the giant sequoia range in 2021, and mortality from those is currently estimated to impact another 5% of the mature trees. As a result, both forests have experienced significant losses in total acreage and potentially a loss of genetic diversity as well. With these significant impacts to both populations, the League is leading restoration projects in both forest ranges. It aims to use this and future genetic research to inform efforts to restore and maintain genetic diversity and bolster the resilience of these species in the face of rapid, unprecedented environmental change. “This ambitious scientific research provides a critical foundation for the League and the entire redwoods community. It will ultimately help us understand the incredible range of responses that coast redwood and giant sequoia species have exhibited in the face of climate change and how native genetic diversity has informed these responses,” says Joanna Nelson, Ph.D., director of science and conservation planning for Save the Redwoods League. “The Redwood Genome Project helps us see, for the first time, the full genetic diversity that has allowed these forests to adapt and survive for millennia — and could protect them against a suite of conditions they have never experienced.” The Redwood Genome Project is made possible by Save the Redwoods League, University of California, Davis, Johns Hopkins University, University of Connecticut and Northern Arizona University. Generous donors of Save the Redwoods League have contributed more than $1 million to the project through Forever Forest: The Campaign for the Redwoods, including a significant lead gift from Ralph Eschenbach and Carol Joy Provan. In addition, genomic services companies Illumina, Oxford Nanopore Technologies and Dovetail Genomics contributed in-kind. To learn more about and support this groundbreaking initiative, visit the League’s website at SaveTheRedwoods.org/Genome. *** To schedule an interview, contact Robin Carr at (415) 971-3991 or redwoods@landispr.com. Save the Redwoods League One of the nation’s longest-running conservation organizations, Save the Redwoods League has been protecting and restoring redwood forests since 1918. The League has connected generations of visitors with the beauty and serenity of the redwood forest. The nonprofit’s 29,000 members have enabled the organization to protect more than 216,000 acres of irreplaceable forest in 66 local, state and national parks and reserves. For information, please visit SaveTheRedwoods.org. University of California, Davis UC Davis is a public institution, land-grant university and pioneer in interdisciplinary problem-solving. Its four colleges, five professional schools, more than 100 academic majors and 90 graduate programs make it the most comprehensive of all the University of California campuses. Johns Hopkins University Johns Hopkins is America’s first research university. For more than 140 years Johns Hopkins has been a world leader in both teaching and research, with nine academic divisions — the Krieger School of Arts and Sciences, the Whiting School of Engineering, the Bloomberg School of Public Health, the Carey Business School, the Peabody Institute, the Paul H. Nitze School of Advanced International Studies, and the schools of Medicine, Nursing, and Education — plus the Applied Physics Laboratory, a nonacademic division that supports national security and pursues space science. The University of Connecticut The University of Connecticut is a national leader among public research universities, with more than 32,000 students seeking answers to critical questions in classrooms, labs, and the community. A culture of innovation drives this pursuit of knowledge throughout the University’s network of campuses. Connecticut’s commitment to higher education helps UConn attract students who thrive in the most competitive environments, as well as globally renowned faculty members. Our school pride is fueled by a history of success that has made us a standout in Division I athletics. UConn fosters a diverse and vibrant culture that meets the needs and seizes the opportunities of a dynamic global society. Northern Arizona University Northern Arizona University is a high-research institution providing exceptional educational opportunities in Arizona and beyond. NAU delivers a student-centered experience to its nearly 30,000 students in Flagstaff, statewide and online through rigorous academic programs in a supportive, inclusive and diverse environment. Dedicated, world-renowned faculty help ensure students achieve academic excellence, experience personal growth, have meaningful research opportunities and are positioned for personal and professional success. ### Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 redwoods@landispr.com Company Website https://www.savetheredwoods.org/

December 16, 2021 12:15 AM Pacific Standard Time

Image

American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Tornadoes in Six States

American Kidney Fund

, The American Kidney Fund (AKF) has activated its Disaster Relief Program to provide emergency grants to dialysis and post-transplant patients who were impacted by the devastating tornadoes on December 10 and 11. AKF’s Disaster Relief Program is the nation’s only rapid-response system that provides emergency financial assistance to dialysis and recent transplant patients. “We were devastated by the news of the tornadoes and our hearts go out to the communities impacted. Through our Disaster Relief Program, we will aid dialysis and post-transplant patients who were affected,” said LaVarne A. Burton, AKF President and CEO. “Our grants provide assistance when it is needed the most and help alleviate some of the financial and health concerns of patients who find themselves navigating the aftermath of a natural disaster.” Emergency grants of $250 are being made available for dialysis and post-transplant patients impacted by the tornadoes in Kentucky, Arkansas, Illinois, Mississippi, Missouri, and Tennessee. Disaster relief grants from AKF help patients replace lost medications and special renal diet foods, pay for temporary housing and transportation to treatment, and replace clothing and personal essentials lost due to the natural disaster or the need to evacuate without notice. AKF has been providing emergency disaster financial assistance to kidney patients throughout all the major disasters that have struck the United States and its territories for the past two decades. Earlier this year, AKF allocated $325,000 to more than 1,600 dialysis and post-transplant patients during the Texas winter storm crisis and $150,000 in emergency grants to more than 750 dialysis and kidney transplant patients affected by Hurricane Ida. AKF also activated its Coronavirus Emergency Fund in March 2020, providing over $3.1 million in assistance to nearly 13,000 dialysis and transplant patients during the pandemic. Dialysis and recent kidney transplant patients who need emergency financial help should contact a social worker at their dialysis clinic for information on applying for aid or apply directly at gms.KidneyFund.org. Applications will be accepted until Dec. 31. Charity Navigator has recognized AKF as one of the four-star charities providing emergency assistance in the aftermath of the tornadoes. AKF is covering the cost of processing and distributing grants, so that 100% of donations to the AKF Disaster Relief Program will be used to assist kidney patients affected by the tornadoes. ### About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details American Kidney Fund Stefanie Tuck +1 202-470-1797 AKF@jpa.com Company Website https://www.kidneyfund.org/

December 15, 2021 10:30 AM Eastern Standard Time

Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic

Variational AI

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company has generated and ordered compounds for validation in partnership with the University of British Columbia (UBC) and adMare BioInnovations to develop a novel SARS-CoV-2 Main Protease (3CLpro) inhibitor. The therapeutic is intended to be efficacious against the wild type and current variants of concern, including Delta and potentially Omicron, in the form of an antiviral pill. The COVID-19 drug discovery program is funded by Canada’s Digital Technology Supercluster, which is supported by the Canadian Ministry of Innovation, Science and Industry. “The Variational AI team is honored to partner with the University of British Columbia and adMare BioInnovations to work to address this most urgent medical need,” said Handol Kim, co-founder and CEO, Variational AI. “As society continues to grapple with COVID-19 variants, it is more important than ever to leverage the power of machine learning to accelerate our drug discovery efforts.” Variational AI has trained its generative AI algorithm on a large amount of COVID-19 data to generate new molecules and has ordered a number of compounds to be synthesized that are predicted to be potent and safe with fewer side effects. Variational AI uses a generative model known as Variational Autoencoder (VAE), which is able to optimize molecular properties more quickly and uses data far more efficiently. The company intends to license the antiviral compound to a partner to accelerate progress and get the therapeutics into clinics sooner. “We are proud to support Variational AI’s innovative approach to discovering an effective therapeutic for COVID-19,” said Sue Paish, CEO of the Digital Technology Supercluster. “While vaccines offer the first and best line of defense against COVID-19, the global community needs as many therapeutic options as possible to prevent fatalities and improve patient outcomes.” Generally, pills can be manufactured, distributed and stored more easily and cost-effectively than vaccines and are particularly well-suited to treat people in developing countries. In addition to COVID-19 and its variants, the resulting therapeutic may also be efficacious against other coronaviruses. “Our lab is committed to remaining at the forefront of applying computational methods to discover COVID-19 therapeutics, and our collaboration with Variational AI to leverage the company’s powerful AI adds a promising pipeline of novel and potent SARS-CoV-2 Main Protease inhibitors to the arsenal of antiviral options,” said Artem Cherkasov, Ph.D., professor of medicine, University of British Columbia. About Variational AI Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing its own internal pipeline. To learn more, visit https://variational.ai. Contact Details Sage Morander +1 401-490-9700 variationalai@svmpr.com Company Website https://variational.ai/

December 15, 2021 10:00 AM Eastern Standard Time

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ), which will take place virtually from January 25, 2022 to January 27, 2022. “There is significant worldwide interest in the clinical application of anti-TGF-β inhibitors, in combination with checkpoint inhibitors, as well as other immuno-oncology and chemotherapeutic options. We look forward to sharing the clinical promise of OT-101 in this setting.” noted Dr. Anthony Maida, Chief Clinical Office – Translational Medicine. TGF-β has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling. But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry. However, the field appears to be at a tipping point at present, with more candidates moving through clinical evaluation, pointing to an explosion of new data on the way. “I am excited that we have the opportunity to join other professionals in the field in January to explore novel insights into targeting TGF-β from discovery through clinical testing, and to learn from fellow colleagues such as Genentech, AbbVie, Takeda, and Mestag Therapeutics.” noted Dr. Vuong Trieu, CEO and Chairman of Oncotelic. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β through therapeutic use of OT-101 carries significant potential to help both cancer and COVID patients in the future. Recent analyst report for Oncotelic can be accessed here: http://www.hillsresearch.com/wp-content/uploads/2021/12/OTLC-3Q21.pdf Recent Dr. Anthony Maida interview on our clinical program can be accessed here: https://www.asbestos.com/news/2021/12/07/mesothelioma-trial-covid-19-drug/ About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. For more information, please visit www.oncotelic.com Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-beta therapeutics for oncology and virology This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate", "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Details Amit Shah ashah@oncotelic.com Company Website https://www.oncotelic.com

December 14, 2021 09:01 AM Eastern Standard Time

Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease

Quidel Corporation

With Lyme disease being identified in record numbers throughout the country, Quidel releases a series of consumer-friendly infographics to help educate Americans on its characteristics, warning signs, seasonality and areas of prevalence. The infographics can be found at LymeDiseaseAnswers.com. “Lyme disease afflicts nearly 480,000 Americans each year; so people are rightfully concerned about where it is most pervasive, how to avoid getting it, and what to do if you think you may have been bitten by an infected tick,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel Corporation. “These infographics provide the information people are seeking in an easy-to-understand manner, and we encourage anyone who spends any time outdoors to educate themselves on this vitally important topic.” One infographic, for example, displays the early warning signs of Lyme disease—which could include headache, fatigue, a bulls-eye rash and muscle aches—while a second infographic depicts such late-stage symptoms as nerve pain, shortness of breath, brain fog and heart palpitations. There is an infographic showing the relative sizes of the larva, nymph and adult ticks; while still another infographic illustrates the evolution of these ticks through spring, summer, fall and winter. There is also a map showing those states where various types of ticks are most prevalent. Lyme disease can strike anyone of any age, especially those who spend time in wooded or grassy areas or who play sports on grass fields in high-risk areas of the country. The challenge is that unlike a mosquito bite where people know immediately if they have been bitten, deer ticks that may carry Lyme disease are tiny—the size of a poppy seed—and symptoms may not appear for two to six weeks. That makes it critically important that anyone who spends time outdoors in heavily wooded areas—hikers, hunters, campers—or travels to such places be particularly vigilant and educated. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia® 2 Lyme FIA test. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office or local clinic; and it is the only test that can get results from a simple finger prick of blood. In addition to the infographics, LymeDiseaseAnswers.com contains answers to frequently asked questions, the latest statistics and clinical research taking place regarding the disease, and links to additional resources on the subject. Also housed on the site is a series of attention-grabbing educational videos called “Quick Takes” that help consumers and health care professionals alike enhance their knowledge of Lyme disease by providing the information and up-to-the-minute data needed to confront this disease quickly and clearly. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, SofiaÂ®, SolanaÂ®, LyraÂ®, TriageÂ® and QuickVueÂ®, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. # # # Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

December 14, 2021 06:00 AM Pacific Standard Time

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the Israel Innovation Authority (IIA). This brings the total amount of financing raised by Kadimastem in 2021 to NIS 51.6 million ($16 M). As Kadimastem intends to submit the IND for the Phase IIa clinical study before the end of 2022, the IIA funding will be used to scale up the production of a frozen, off-the-shelf product of AstroRx® in preparation for the trial. Using large reactors and special tools, hundreds of millions of high-quality astrocyte cells, the brain supporting cells that comprise AstroRx®, will be produced for the clinical trial, as well as for future commercialization purposes for the benefit of the hundreds of thousands of ALS patients worldwide. Kadimastem has already completed a Phase I/IIa clinical trial ( ClinicalTrials.gov Identifier: NCT03482050 ). This trial was the first of its kind in the world, whereby the supporting cells of the central nervous system (AstroRx®), produced by the company, were injected into the spinal fluid of patients, in a standard lumbar puncture procedure. Five ALS patients were injected with 100 million cells and five patients were injected with 250 million cells. The results of both doses demonstrated a high safety profile. No serious treatment-related side effects were reported and no side effects limiting the treatment dose were found. In order to determine initial efficacy, an analysis was performed comparing the rate of disease progression according to the ALSFRS-R index in the pre-treatment follow-up period and the post-treatment follow-up period. It was found that with both doses the rate of disease progression slowed significantly during the three months following injection. In light of these clinical trial results, in the next study, the company intends to examine if dosing every three months with the cellular off-the-shelf AstroRx® product prolongs the therapeutic effect. Kadimastem CEO Asaf Shiloni said, "In the past year, Kadimastem has experienced an unprecedented show of support from both existing and new investors. Today’s grant by the Israeli Innovation Authority is another strong endorsement of the company’s important work in developing an improved therapeutic treatment for the millions suffering from debilitating neurological diseases. Kadimastem is at an exciting turning point and this grant supports us with the necessary resources to advance the plans for the quantitative production of the company's flagship product - AstroRx®. In other words, after this past year’s fund raising, we now have the capital to create increased quantities of brain supporting cells, enough to truly make a big difference in helping the hundreds of thousands of ALS patients worldwide." Chief Scientist of Kadimastem Professor Michel Revel said, "We thank the Israel Innovation Authority for its continued support and for further helping Kadimastem to proceed on this very worthwhile journey." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin-dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. In November 2021, the company announced its intention to list on NASDAQ. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

December 13, 2021 07:00 AM Eastern Standard Time

Image

Healthcare

Record 40,000 Transplants Honors Legacy of Donors

METER Group Unveils Major Update to AQUALAB Vapor Sorption Analyzer Software

Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California

Completed Redwood Genome Sequence Reveals Genes for Climate Adaptation and Offers Insights into Genetic Basis for Survival

American Kidney Fund Activates Disaster Relief Program to Support Dialysis and Post-Transplant Patients Affected by Tornadoes in Six States

Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority